Despite Amplified Use of SGLT2 Inhibitors for Glomerular Diseases, EU and US Nephrologists Express a Continued Strong Desire for New Treatment Options for FSGS Patients, Spherix Reports

Nephrologists are most anticipating sparsentan (Travere, co-marketed with Vifor in EU), with Vertex’s pipeline product VX-147 following closely behind – according to new research from Spherix Global Insights EXTON, PA., Sept. 21, 2022 /PRNewswire/ — Focal segmental glomerulosclerosis…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.